Related Experiment Videos
[Pharmacokinetic studies on ceftazidime in neonates]
The Japanese Journal of Antibiotics
|August 1, 1986
Summary
The pharmacokinetics of ceftazidime (CAZ) in neonates show variable serum levels and half-lives influenced by age. Understanding these ceftazidime pharmacokinetics is crucial for appropriate dosing in newborns.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Antibiotic Pharmacokinetics
Context:
- Neonates exhibit unique physiological differences affecting drug metabolism.
- Ceftazidime (CAZ) is an important antibiotic for treating neonatal infections.
- Accurate pharmacokinetic data is essential for safe and effective neonatal drug therapy.
Purpose:
- To characterize the pharmacokinetics of ceftazidime in neonates.
- To evaluate the impact of postnatal age on ceftazidime serum concentrations and elimination.
- To provide data for optimizing ceftazidime dosing regimens in the neonatal population.
Summary:
- Intravenous ceftazidime administration at 10 mg/kg and 20 mg/kg resulted in peak serum levels within 15 minutes to 1 hour across various neonatal ages.
- Serum concentrations declined over 6 hours, with half-lives ranging from approximately 2 to 3.3 hours, showing some age-related variability.
- Higher doses generally led to higher peak serum levels and concentrations at 6 hours, indicating dose-dependent exposure.
Impact:
- This study provides critical pharmacokinetic parameters for ceftazidime in neonates.
- Findings can inform evidence-based dosing guidelines to improve therapeutic efficacy and minimize toxicity.
- Understanding ceftazidime's behavior in neonates aids in managing serious bacterial infections in this vulnerable population.